BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, Cauli A. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage. Arthritis Care Res (Hoboken) 2020;72:1794-9. [PMID: 31600023 DOI: 10.1002/acr.24086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel BA, Alarcón GS. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2022:annrheumdis-2022-222487. [PMID: 35944946 DOI: 10.1136/ard-2022-222487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Samões B, Zen M, Abelha-Aleixo J, Gatto M, Doria A. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus. Autoimmun Rev 2022;21:103165. [PMID: 35931316 DOI: 10.1016/j.autrev.2022.103165] [Reference Citation Analysis]
3 Piga M, Chessa E, Morand EF, Ugarte-gil MF, Tektonidou M, van Vollenhoven R, Petri M, Arnaud L, Appenzeller S, Aranow C, Askanase A, Avcin T, Bae S, Bertsias G, Bonfa E, Cairoli E, Cardiel MH, Cervera R, Chasset F, Chizzolini C, Clarke AE, Conti F, Costedoat-chalumeau N, Czirják L, Doria A, Dörner T, Espinosa G, Fischer-betz R, Garcìa M, Gladman DD, González LA, Gunnarsson I, Hamijoyo L, Hanly JG, Hasni SA, Houssiau FA, Inanç M, Inês LS, Isenberg D, Jacobsen S, Jan Wu Y, Kaneko Y, Katsumata Y, Lau CS, Legge AC, Lerang K, Limper M, Louthrenoo W, Luo S, Marinho A, Massardo L, Mathian A, Mosca M, Nikpour M, Pego-reigosa JM, Peschken CA, Pons-estel BA, Pons-estel GJ, Rahman A, Rednic S, Ribi C, Ruiz-irastorza G, Sato EI, Saxena A, Schneider M, Sebastiani GD, Strand V, Svenungsson E, Tanaka Y, Tazi Mezalek Z, Tee ML, Tincani A, Touma Z, Troldborg A, Vasconcelos C, Vinet É, Vital EM, Voskuyl AE, Voss A, Wallace D, Ward M, Zamora LD. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. The Lancet Rheumatology 2022;4:e441-9. [DOI: 10.1016/s2665-9913(22)00107-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ugarte-Gil MF, Mendoza-Pinto C, Reátegui-Sokolova C, Pons-Estel GJ, van Vollenhoven RF, Bertsias G, Alarcon GS, Pons-Estel BA. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. Lupus Sci Med 2021;8:e000542. [PMID: 34548375 DOI: 10.1136/lupus-2021-000542] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Golder V, Tsang-A-Sjoe MWP. Treatment targets in SLE: remission and low disease activity state. Rheumatology (Oxford) 2020;59:v19-28. [PMID: 33280016 DOI: 10.1093/rheumatology/keaa420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
6 Piga M, Floris A, Sebastiani GD, Prevete I, Iannone F, Coladonato L, Govoni M, Bortoluzzi A, Mosca M, Tani C, Doria A, Iaccarino L, Franceschini F, Fredi M, Conti F, Spinelli FR, Galeazzi M, Bellisai F, Zanetti A, Carrara G, Scirè CA, Mathieu A. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology (Oxford) 2020;59:2272-81. [PMID: 31840179 DOI: 10.1093/rheumatology/kez584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
7 Piga M, Arnaud L. The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? J Clin Med 2021;10:E243. [PMID: 33440874 DOI: 10.3390/jcm10020243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 [DOI: 10.1101/2020.04.14.20064683] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]